We’re pleased to share that #Biogen received a positive CHMP opinion from #EMA for a proposed rheumatoid arthritis #biosimilar , based on a robust analytical, non-clinical and clinical data package comparing the product to the reference biologic. Read more: ow.ly/wmu650RosWo

STARTING SOON: Our Q1 2024 financial results live webcast starts at 8:30 AM ET. Register for the webcast here: ow.ly/aPg350RmG9S

#Earnings $BIIB

Read our Q1 2024 financial results here: ow.ly/CIRu50RmFk3

#Earnings $BIIB

The 20th #Biosimilar Medicines Conference ( #BIOS24 ) starts tomorrow! Join us during session 5 on Reforming EU and National Market Policies. It’s a great chance to learn about the national market dynamics that profoundly influence biosimilar competition: bit.ly/3xH1etHddd

Biogen will report Q1 financial results, April 24 before markets open in the U.S.: ow.ly/A2JQ50RbNsh

#Earnings $BIIB

We’re headed to Lisbon, Portugal this week for #ADPD24 (AD/PD - Advances in Science & Therapy). We’re looking forward to sharing the latest research from our Alzheimer’s disease portfolio and connecting with the medical community. Learn more: ow.ly/MgXF50QMZgP

We are presenting data from ongoing studies and new updates from our spinal muscular atrophy ( #SMA ) research at the 2024 #MDAconference . Learn more: ow.ly/5NTG50QMuAr

We’re proud to share CEO Chris Viehbacher was named to STAT 2024 Status List – read more here: ow.ly/MvS450QINxz

We’ve received a positive opinion from the European Medicine Agency’s Committee for Medicinal Products for Human Use (CHMP) for our treatment for amyotrophic lateral sclerosis ( #ALS ) in adults who have a specific gene mutation. Learn more about this news: bit.ly/4bP14ju

This morning we reported our Q4 and Full-Year 2023 Financial Results. See highlights from our webcast below and watch the full recording here: ow.ly/koNb50QAJIg

#Earnings $BIIB

STARTING SOON: Our Q4 and Full-Year 2023 Financial Results live webcast starts at 8:00 AM ET. Register for the webcast here: bit.ly/4buR2nz

#Earnings $BIIB

Read our Q4 and Full-Year 2023 Financial Results here: ow.ly/uctb50QAnKU

#Earnings $BIIB

We’re pleased to share that we’ve received approval from the European Commission for our #FriedreichsAtaxia (FA) therapy in people aged 16 years and older. This is the first treatment approved in the European Union for FA, a rare neurodegenerative disease: bit.ly/49wZfFT

Today we announced plans to reprioritize our resources in Alzheimer’s disease, a strategic therapeutic area expected to drive near and long-term growth. Read our news release: investors.biogen.com/news-releases/…

It’s a common misconception that #AlzheimersDisease (AD) only impacts those who are age 65+. However, early-onset AD can affect adults under this age. Watch to learn more about how age impacts those living with AD:

The progression and distribution of tau in the brain is tied to symptoms in #AlzheimersDisease . Using what we know and recognizing what we don’t know about the protein is key to developing potential treatments. Read more: ow.ly/elc750Q638L

We’re excited to announce our participation at #ACR23 in San Diego where we’ll share additional data from our #lupus research programs. Learn more about the meeting: ow.ly/J4WY50Q6nTZ

Data from our early-stage #Alzheimers disease research has been published by JAMA Neurology.

Learn more: ow.ly/WBSS50Q3aZu

#BiotechNews

At Biogen, we strive for an advanced understanding of medications to ensure safety and proper use for all.

Join us during this #MedSafetyWeek , where we emphasize the importance of staying vigilant and reporting adverse events and reactions. ow.ly/Iytb50Q5zUZ

This morning we reported our third quarter 2023 financial results. A replay of the webcast is now available: ow.ly/lYhT50Q0oNT

#Earnings $BIIB